Cargando…
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells
BACKGROUND: The cyclin-dependent kinase (CDK) inhibitor p27(Kip1 )is downregulated in a majority of human cancers due to ectopic proteolysis by the ubiquitin-proteasome pathway. The expression of p27 is subject to multiple mechanisms of control involving several transcription factors, kinase pathway...
Autores principales: | Rico-Bautista, Elizabeth, Yang, Chih-Cheng, Lu, Lifang, Roth, Gregory P, Wolf, Dieter A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025922/ https://www.ncbi.nlm.nih.gov/pubmed/21182779 http://dx.doi.org/10.1186/1741-7007-8-153 |
Ejemplares similares
-
p27(Kip1) and Ser10-phosphorylated p27(Kip1) in breast cancer: clinical significance and expression
por: Song, Wei, et al.
Publicado: (2015) -
Regulation of p27(Kip1) and p57(Kip2) Functions by Natural Polyphenols
por: Russo, Gian Luigi, et al.
Publicado: (2020) -
p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma
por: Currier, Arthur W., et al.
Publicado: (2019) -
p27(kip1): a target for tumor therapies?
por: Nickeleit, Irina, et al.
Publicado: (2007) -
p27(Kip1) regulates alpha-synuclein expression
por: Gallastegui, Edurne, et al.
Publicado: (2018)